Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-02-24

FDA Approved: ABACAVIR AND LAMIVUDINE — Supplemental Application (Lupin Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved Lupin Pharmaceuticals' supplemental application for a generic fixed-dose combination tablet of abacavir and lamivudine for HIV infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ABACAVIR AND LAMIVUDINE (abacavir/lamivudine)

Snippet

SUPPL AP for ABACAVIR AND LAMIVUDINE (ABACAVIR AND LAMIVUDINE)